Review of Cancer Risk and Hormone Therapy
“Women and their healthcare providers should feel reassured about the safety of hormone therapy when used at menopause.”
Joanne pinkerton, MD, FACOG, NCMP
professor of obstetrics and gynecology, director of midlife health at UVA Health and executive director emeritus of the North American Menopause Society
A new review examined trial and observational study data and concluded that when prescribed to women after a hysterectomy, estrogen therapy used alone at menopause did not increase the risk of invasive breast cancer. Longer durations of estrogen therapy use may increase risk. For women who still have their uterus and use combined estrogen and progestogen, especially long-term, breast cancer risk increased slightly but did not translate into a higher risk of death.
Authors of an editorial, including the past medical director of the North American Menopause Society, recommend that patients and their doctors reevaluate whether to continue the treatment periodically while continuing with breast examinations and breast imaging.
For guidance on cancer and menopause, download Midday from the App Store or visit us at Midday.Health.
Related Content
Revolutionizing Workplace Inclusivity: New Research on Menopause and Work
New study by SRI International and Lisa Health uncovers challenges faced by menopausal women in the workplace.
Measuring Perimenopause Hormone Levels
Perimenopause hormone testing is not as straightforward as it may seem.
Is It Heavy Perimenopause Bleeding or Something Else?
Learn how to handle heavy and irregular perimenopause bleeding and when to seek professional advice to ensure your health and well-being.
Sign up for more unique women’s health content
By submitting this form, you agree to the Lisa Health Privacy Policy and Terms of Use